Long-acting PEGylated growth hormone in children with idiopathic short stature.
Xiaoping LuoSha ZhaoYu YangGuanping DongLinqi ChenPin LiFeihong LuoChun-Xiu GongZhuangjian XuXu XuHaihong GongHongwei DuLing HouYan ZhongQiao ShiXuefeng ChenXiuli ChenLiya XuRuoqian ChengChang SuYaping MaLulian XuLina ZhangHonghua LuPublished in: European journal of endocrinology (2022)
Fifty-two-week treatment with PEG-rhGH 0.1 or 0.2 mg/kg/week achieved significant improvement in HT-SDS and other growth-related variables, including HV, IGF-1 SDS, and IGF-1/IGFBP-3 ratio, in a dose-dependent manner. Both doses were well tolerated with similar safety profiles.